Molecular risk prediction in cutaneous melanoma: A meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients

• Published in: Journal of the American Academy of Dermatology 2020-09, Vol.83 (3), p.745-753
• Main Authors: Greenhaw, Bradley N., Covington, Kyle R., Kurley, Sarah J., Yeniay, Yildiray, Cao, Nhat Anh, Plasseraud, Kristen M., Cook, Robert W., Hsueh, Eddy C., Gastman, Brian R., Wei, Maria L.
• Format: Article
• Language: English
• Subjects: 31-GEP; Biomarkers, Tumor - genetics; Disease-Free Survival; Feasibility Studies; Gene Expression Profiling; genomics; Humans; Kaplan-Meier Estimate; melanoma; Melanoma - diagnosis; Melanoma - genetics; Melanoma - mortality; Melanoma - therapy; meta-analysis; metastasis; molecular classification; Neoplasm Recurrence, Local - epidemiology; Neoplasm Recurrence, Local - genetics; Neoplasm Staging; Predictive Value of Tests; Prognosis; recurrence; Risk Assessment - methods; Skin Neoplasms - diagnosis; Skin Neoplasms - genetics; Skin Neoplasms - mortality; Skin Neoplasms - therapy; survival; Survival Rate
• ISSN: 0190-9622; 1097-6787
• DOI: 10.1016/j.jaad.2020.03.053

Multiple studies have reported on the accuracy of the prognostic 31-gene expression profile test for cutaneous melanoma. Consistency of the test results across studies has not been systematically evaluated. To assess the robustness of the prognostic value of the 31-gene expression profile. Raw data were obtained from studies identified from systematic review. A meta-analysis was performed to determine overall effect of the 31-gene expression profile. Clinical outcome metrics for the 31-gene expression profile were compared with American Joint Committee on Cancer staging. Three studies met inclusion criteria; data from a novel cohort of 211 patients were included (n = 1,479). Five-year recurrence-free and distant metastasis-free survival rates were 91.4% and 94.1% for Class 1A patients and 43.6% and 55.5% for Class 2B patients (P